advertisement
the lower efficacy in the astrazeneca and janssen trials may also be explained by a greater number of infections from variants of concern, which emerged after the pfizer and moderna trials were completed and against which vaccine protection is expected to be lower . in the janssen trial, for example, efficacy was 74 per cent in the united states but dropped to 52 per cent in south africa, where almost 95 per cent of cases were due to the b.1.351 variant. at least 136 cases of this variant had been detected in canada as of march 8.
advertisement
comparisons should also take into account differences in the number and timing of doses. however, the national advisory committee on immunization expects that short-term efficacy will likely remain high, even with an extended four-month interval between doses.
the national advisory committee on immunization advised in early march against using the astrazeneca shot in adults aged 65 years and older, citing a lack of efficacy data for that age group. as more data comes in, “we’ll be able to make better decisions about who ought to get which vaccines,” thompson predicts.
advertisement
advertisement
allergic reactions like anaphylaxis are rare but treatable complications. they occur most often in people with a history of allergic reactions .
advertisement
as of march 8, canada had administered a total of 2.5 million doses. across canada, almost two million people have gotten at least one dose and more than 579,000 people, or about 2 per cent of the adult population, are fully vaccinated. canada has signed agreements for up to 180 million doses in total with manufacturers of the four authorized vaccines: up to 76 million doses for pfizer, 44 million for moderna, 22 million for astrazeneca and up to 38 million for janssen.
advertisement